DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHOD OF USE

1 . A compound of Formula (I):

or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof,

wherein:

ring A and B are each independently an aromatic ring comprising 0-3 heteroatoms selected from nitrogen, sulfur and oxygen as ring member(s);

Z 1 , Z 2 , Z 3 and Z 4 are each independently N or CR z ;

L is independently a bond, —C 1-8 alkylene-, —N(R 4 )—, —O—, —S—, * L —C 1-8 alkylene-O—** L , * L —O—C 1-8 alkylene-** L , * L —N(R 4 )CO—** L , * L —CON(R 4 )—** L , * L —N(R 4 )CO—C 1-8 alkylene-** L , * L —CON(R 4 )—C 1-8 alkylene-** L , * L —N(R 4 )—C 1-8 alkylene-** L , * L —C 1-8 alkylene-N(R 4 )—** L , -heterocyclene-, or -heteroarylene-, wherein each of said —C 1-8 alkylene-, * L —C 1-8 alkylene-O—** L , * L —O—C 1-8 alkylene-** L , * L —N(R 4 )CO—C 1-8 alkylene-** L , * L —CON(R 4 )—C 1-8 alkylene-** L , * L —N(R 4 )—C 1-8 alkylene-** L , * L —C 1-8 alkylene-N(R 4 )—** L , -heterocyclene- and -heteroarylene- is optionally substituted with at least one substituent R L ;

wherein * L refers to the position attached to ring A, and ** L refers to the position attached to ring B;

m, n and q are each independently 0, 1, 2, 3 or 4;

t is 0, 1 or 2;

R 1 , R 2 , and R 4 are each independently hydrogen, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each of said —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with halogen, hydroxy, —C 1-8 alkyoxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl;

R L , R 3 , R 5 and R 6 are each independently hydrogen, halogen, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, —CN, —NO 2 , —OR a , —SO 2 R a , —COR a , —CO 2 R a , —CONR a R b , —C(═NR a )NR b R c , —NR a R b , —NR a COR b , —NR a CONR b R c , —NR a CO 2 R b , —NR a SONR b R c , —NR a SO 2 NR b R c , or —NR a SO 2 R b , wherein each of said —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with at least one halogen, hydroxy, —C 1-8 alkyl, —C 1-8 alkyoxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl;

R z is selected from the bond between

moiety and

moiety, hydrogen, halogen, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, —CN, —NO 2 , —OR a , —SO 2 R a , —COR a , —CO 2 R a , —CONR a R b , —C(═NR a )NR b R c , —NR a R b , —NR a COR b , —NR a CONR b R c , —NR a CO 2 R b , —NR a SONR b R c , —NR a SO 2 NR b R c , or —NR a SO 2 R b , each of said —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with at least one halogen, hydroxy, —C 1-8 alkyl, —C 1-8 alkyoxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl;

R a , R b , and R c are each independently hydrogen, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl;

or two R L , together with the atom(s) to which they are attached, form a 3- to 12-membered ring, said ring comprising 0, 1 or 2 additional heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur as ring member(s), said ring is optionally substituted with at least one substituent independently selected from halogen, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, —CN, —NO 2 , —OR 3f , —SO 2 R 3f , —SO 2 NR 3f R 3g , —COR 3f , —CO 2 R 3f , —CONR 3f R 3g , —C(═NR 3f )NR 3g R 3h , —NR 3f R 3g , —NR 3f COR 3g , —NR 3f CONR 3g R 3h , —NR 3f CO 2 R 3f , —NR 3f SONR 3f R 3g , —NR 3f SO 2 NR 3g R 3h , or —NR 3f SO 2 R 3g , each of said —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with at least one substituent selected from halogen, —C 1-8 alkyl, —OR 3i , —NR 3i R 3j , cycloalkyl, heterocyclyl, aryl, or heteroaryl;

or two R 3 , together with the atoms to which they are attached, form a 3- to 12-membered ring, said ring comprising 0, 1 or 2 additional heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur as ring member(s), said ring is optionally substituted with at least one substituent independently selected from halogen, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, —CN, —NO 2 , —OR 3f , —SO 2 R 3f , —SO 2 NR 3f R 3g , —COR 3f , —CO 2 R 3f , —CONR 3f R 3g , —C(═NR 3f )NR 3g R 3h , —NR 3f R 3g , —NR 3f COR 3g , —NR 3f CONR 3g R 3h , —NR 3f CO 2 R 3f , —NR 3f SONR 3f R 3g , —NR 3f SO 2 NR 3g R 3h , or —NR 3f SO 2 R 3g , each of said —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with at least one substituent selected from halogen, —C 1-8 alkyl, —OR 3i , —NR 3i R 3j , cycloalkyl, heterocyclyl, aryl, or heteroaryl;

or R 4 and one of R 3 , together with the atoms to which they are attached, form a 3- to 12-membered ring, said ring comprising 0, 1 or 2 additional heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur as ring member(s), said ring is optionally substituted with at least one substituent independently selected from halogen, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, —CN, —NO 2 , —OR 3f , —SO 2 R 3f , —SO 2 NR 3f R 3g , —COR 3f , —CO 2 R 3f , —CONR 3f R 3g , —C(═NR 3f )NR 3g R 3h , —NR 3f R 3g , —NR 3f COR 3g , —NR 3f CONR 3g R 3h , —NR 3f CO 2 R 3f , —NR 3f SONR 3f R 3g , —NR 3f SO 2 NR 3g R 3h , or —NR 3f SO 2 R 3g , each of said —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with at least one substituent selected from halogen, —C 1-8 alkyl, —OR 3i , —NR 3i R 3j , cycloalkyl, heterocyclyl, aryl, or heteroaryl;

R 3f , R 3g , R 3h , R 3i , and R 3j are each independently hydrogen, —C 1-8 alkyl, C 1-8 alkoxy-C 1-8 alkyl-, —C 2-8 alkenyl, —C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl;

the Linker is a bond or a divalent linking group, and

the Degron is an E3 Ubiquitin ligase moiety.

2 . The compound according to claim 1 , wherein the Degron moiety is selected from Formulas D1, D2 or D3:

wherein, at each of its occurrences,

Y 2 and Y 3 are each independently —CH 2 —, —NH— or —C(O)—;

L 0 is selected from a bond, —CH 2 —, —O—, —NH— and —S—; wherein each of Y 2 , Y 3 and L 0 is independently optionally substituted with at least one substituent selected from hydrogen, halogen, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, —CN;

Y 4 , Y 5 , Y 6 , Y 7 and Y 8 are each independently CH or N;

Y 9 is CH or N;

s is 0, 1, 2, 3, or 4;

u is 0, 1, or 2;

R 8 is each independently hydrogen, halogen, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, —CN, —NO 2 , —OR 8a , —SO 2 R 8a , —COR 8a , —CO 2 R 8a , —CONR 8a R 8b , —C(═NR 8a )NR 8b R 8c , —NR 8a R 8b , —NR 8a COR 8b , —NR 8a CONR 8b R 8c , —NR 8a CO 2 R 8b , —NR 8a SONR 8b R 8c , —NR 8a SO 2 NR 8b R 8c , or —NR 8a SO 2 R 8b , each of said —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with halogen, hydroxy, —C 1-8 alkyoxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl; and

R 8a , R 8b , and R 8c are each independently hydrogen, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl.

3 . The compound according to claim 2 , wherein

(a) Formula D1 is selected from

wherein R 8 is defined as in claim 2 ; or

(b) Formula D2 is selected from

4 . (canceled)

5 . The compound according to claim 2 , wherein

(a) Formula D2 is selected from

wherein R 8 is defined as in claim 2 ; or

(b) Formula D2 is selected from

6 . (canceled)

7 . The compound according to claim 2 , wherein

(a) Formula D3 is selected from

wherein R 8 is defined as above;

L 0 is selected from a bond, —CH 2 —, —O—, —NH— and —S—; wherein L 0 is independently optionally substituted with at least one substituent selected from hydrogen, F, Cl, Br, I, —CH 3 , —C 2 H 5 , —C 3 H 7 , —C 4 H 9 , —C 5 H 11 , —C 2-8 alkenyl, —C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, heterocyclyl, aryl, heteroaryl or —CN; or

(b) Formula D3 is selected from

8 . (canceled)

9 . The compound according to claim 1 , wherein

(a) is a bond, —CH 2 —, —C 2 H 4 —, —C 3 H 6 —, —C 4 H 8 —, —C 5 H 10 —, —O—, —NH—, * L —NHCH 2 —** L , * L —NHC 2 H 4 —** L , * L —NHC 3 H 6 —** L , * L —NHC 4 H 8 —** L , * L —NHC 5 H 10 —** L , * L —OCH 2 —** L , * L —OC 2 H 4 —** L , * L —OC 3 H 6 —** L , * L —OC 4 H 8 —** L , * L —OC 5 H 10 —** L , * L —CH 2 O—** L , * L —C 2 H 40 —** L , * L —C 3 H 60 —** L , * L —C 4 H 8 O—** L , * L —C 5 H 10 O—** L , * L —CONH—** L , * L —NHCO—** L , * L —CONHCH 2 —** L , * L —CONHC 2 H 4 —** L , * L —CONHC 3 H 6 —** L , * L —CONHC 4 H 8 —** L , * L —CONHC 5 H 10 —** L ,

3- to 8-membered -heterocyclene- or 5- to 6-membered -heteroarylene-; wherein each of said —CH 2 —, —C 2 H 4 —, —C 3 H 6 —, —C 4 H 8 —, —C 5 H 10 —, —O—, —NH—, * L —NHCH 2 —** L , * L —NHC 2 H 4 —** L , * L —NHC 3 H 6 —** L , * L —NHC 4 H 8 —** L , * L —NHC 5 H 10 —** L , * L —OCH 2 —** L , * L —C 2 H 4 —** L , * L —OC 3 H 6 —** L , * L —OC 4 H 8 —** L , * L —OC 5 H 10 —** L , * L —CH 2 O—** L , * L —C 2 H 40 —** L , * L —C 3 H 6 O—** L , * L —C 4 H 8 O—** L , * L —C 5 H 10 O—** L , * L —CONH—** L , * L —NHCO—** L , * L —CONHCH 2 —** L , * L —CONHC 2 H 4 ** L , * L —CONHC 3 H 6 —** L , * L —CONHC 4 H 8 —** L , * L —CONHC 5 H 10 —** L ,

3- to 8-membered -heterocyclene- and 5- to 6-membered -heteroarylene- is optionally substituted with at least one substituent R L ; wherein R L is defined as in claim 1 ; or

(b) L is a bond, —O—, * L —OCH 2 —** L , * L —CH 2 O—** L , —NH—, * L —CONH—** L , * L —NHCO—** L , * L —CONHCH 2 —** L , * L —CONHCH 2 CH 2 —** L , * L —CONHCH 2 CH 2 CH 2 —** L , * L —CONHCH(CH 3 )—** L , * L —CONHCH(C 2 H 5 )—** L , * L —NHCH 2 —** L , * L —NHCH 2 CH 2 —** L , * L —NHCH 2 CH 2 CH 2 —** L , * L —NHCH(CH 3 )—** L , * L —NHCH(C 2 H 5 )—** L ,

or

(c) L is * L —N(R 4 )CO—** L ,

R 3 and R 4 , together with the atoms to which they are attached, form a 5-, 6- or 7-membered ring, said ring comprising 0, 1 or 2 additional heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur as ring member(s), said ring is optionally substituted with at least one substituent independently selected from —F, —Cl, —Br, —I, —CH 3 , —C 2 H 5 , —C 3 H 7 , —C 4 H 9 , —C 5 H 11 , cycloalkyl, heterocyclyl, aryl, heteroaryl, or oxo.

10 . (canceled)

11 . (canceled)

12 . The compound according to claim 1 , wherein

moiety is

wherein Z 5 , Z 6 , Z 7 , Z 8 , Z 9 , Z 6′ , Z 7′ , Z 8′ and Z 9′ a each independently N or C(H); Z 10 is N(H), O or S;

optionally wherein ring A is a 5- to 6-membered aromatic ring comprising 0-3 heteroatoms selected from nitrogen, sulfur and oxygen as ring member(s);

further optionally wherein ring A is phenyl, naphthalenyl, quinoxalinyl, pyridinyl, pyridazinyl, pyrimidinyl, imidazolyl, thiazolyl, oxazolyl, oxadiazole, pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, furanyl, pyrimidinyl, pyrazinyl or pyrrolopyridinyl; or

(b) the

moiety is

optionally wherein R 3 is hydrogen, —F, —Cl, —Br, —I, —CH 3 , —C 2 H 5 , —C 3 H 7 , —C 4 H 9 , —C 5 H 11 , —OCH 3 , —OC 2 H 5 , —OC 3 H 7 , —OC 4 H 9 , —OC 5 H 11 , cyclopropyl, cyclobutyl, cyclopentyl, tetrahydropyrrolyl or phenyl, wherein each of said —CH 3 , —C 2 H 5 , —C 3 H 7 , —C 4 H 9 , —C 5 H 11 , —OCH 3 , —OC 2 H 5 , —OC 3 H 7 , —OC 4 H 9 , —OC 5 H 11 , cyclopropyl, cyclobutyl, cyclopentyl, tetrahydropyrrolyl or phenyl, is optionally substituted with at least one —F, —Cl, —Br, —I, —CH 3 , —C 2 H 5 , —C 3 H 7 , —C 4 H 9 , —C 5 H 11 , —OCH 3 , —OC 2 H 5 , —OC 3 H 7 , —OC 4 H 9 , —OC 5 H 11 , —OH, cyclopropyl, cyclobutyl or cyclopentyl;

further optionally wherein R 3 is hydrogen, —F, —Cl, —Br, —I, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, trifluoromethyl, difluoromethyl, fluoromethyl, —OMe, —OEt, —OPr, —OBu, cyclopropyl, cyclobutyl, tetrahydropyrrolyl or phenyl;

or optionally wherein two R 3 , together with the atoms to which they are attached, form a 4-, 5-, 6-, 7- or 8-membered ring, said ring comprising 0, 1 or 2 additional heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur as ring member(s), said ring is optionally substituted with at least one substituent independently selected from —F, —Cl, —Br, —I, —CH 3 , —C 2 H 5 , —C 3 H 7 , —C 4 H 9 , —C 5 H 11 , —OCH 3 , —OC 2 H 5 , —OC 3 H 7 , —OC 4 H 9 , —OC 5 H 11 , —OH, —CN, cyclopropyl, cyclobutyl or cyclopentyl; or

(c) the

moiety is

13 .- 19 . (canceled)

20 . The compound according to claim 12 , wherein

(a) the

moiety is

wherein Z 5 , Z 6 , Z 7 and Z 8 are defined as in claim 12 ; or

(b) the

moiety is

or

(c) the

moiety is

21 . (canceled)

22 . The compound according to claim 1 , wherein ring B is phenyl, pyridinyl, imidazolyl, thiazolyl, oxazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, triazolyl, thiophenyl, furanyl, pyrimidinyl or pyrazinyl, each of which is optionally substituted with (R 6 ) q .

23 . The compound according to claim 1 , wherein R 6 is hydrogen, —F, —Cl, —Br, —I, —CH 3 , —C 2 H 5 , —C 3 H 7 , —C 4 H 9 , —C 5 H 11 , —CN, —OCH 3 , —OC 2 H 5 , —OC 3 H 7 , —OC 4 H 9 or —OC 5 H 11 , wherein each of said —CH 3 , —C 2 H 5 , —C 3 H 7 , —C 4 H 9 , —C 5 H 11 , —OCH 3 , —OC 2 H 5 , —OC 3 H 7 , —OC 4 H 9 or —OC 5 H 11 is optionally substituted with —F, —Cl, —Br, —I, hydroxy, —C 1-8 alkyoxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl.

24 . (canceled)

25 . The compound according to claim 1 , wherein

26 . The compound according to claim 1 , wherein

(a) R 1 and R 2 are each independently hydrogen, —CH 3 , —C 2 H 5 , —C 3 H 7 , —C 4 H 9 , —C 5 H 11 , —C 2-8 alkenyl, —C 2-8 alkynyl or aryl; optionally wherein R 1 and R 2 are both H;

and/or

(b) R 5 is independently hydrogen, —F, —Cl, —Br, —I, —CH 3 , —C 2 H 5 , —C 3 H 7 , —C 4 H 9 , —C 5 H 11 , —C 2-8 alkenyl, —C 2-8 alkynyl or aryl,

and/or

(c) R z is independently the bond between

moiety and

moiety, hydrogen, —F, —Cl, —Br, —I, —CH 3 , —C 2 H 5 , —C 3 H 7 , —C 4 H 9 or —C 5 H 11 .

27 .- 29 . (canceled)

30 . The compound according to claim 1 , wherein

is

preferably

31 . The compound according to claim 1 , wherein the

moiety is

32 . The compound according to claim 1 , wherein the

moiety is

wherein * refers to the position attached to the

moiety, and ** refers to the position attached to the

moiety;

X 1 , X 2 , X 3 and X 4 are each independently selected from CH or N;

r and s are each independently 0 or 1;

L 1 is a single bond, —O—, —SO 2 —, —C(O)—, —NR L1a —, —C 3 -C 8 cycloalkylene-, * L —O—C 1-8 alkylene-** L1 , * L1 —C 1-8 alkylene-O—** L1 , * L1 —SO 2 —C 1-8 alkylene-** L1 , * L1 —C 1-8 alkylene-SO 2 —** L1 , * L —C(O)—C 1-8 alkylene-** L1 , * L1 —C 1-8 alkylene-C(O)—** L1 , * L1 —NR L1a —C 1-8 alkylene-** L1 , * L1 —C 1-8 alkylene-NR L1a —** L , * L1 —NR L1a C(O)—** L1 , * L1 —C(O)NR L1a —** L1 , * L1 —NR L1a C(O)C 1-8 alkylene-** L1 , * L1 —C(O)NR L1a C 1-8 alkylene-** L1 , * L1 —C 1-8 alkyleneNR L1a C(O)—** L1 , * L1 —C 1-8 alkyleneC(O)NR L1a —** L , —C 1-8 alkylene-, —C 2-8 alkenylene-, —C 2-8 alkynylene-, or —[O(CR L1a R L1b ) u1 ] v1 —;

each of said —C 3 -C 8 cycloalkylene-, * L —O—C 1-8 alkylene-** L1 , * L1 —C 1-8 alkylene-O—** L1 , * L1 —SO 2 —C 1-8 alkylene-** L1 , * L1 —C 1-8 alkylene-SO 2 —** L1 , * L1 —C(O)—C 1-8 alkylene-** L1 , * L1 —C 1-8 alkylene-C(O)** L1 , * L —NR L1a —C 1-8 alkylene-** L1 , * L1 —C 1-8 alkylene-NR L1a —** L1 , * L1 —NR L1a C(O)C 1-8 alkylene-** L1 , * L1 —C(O)NR L1a C 1-8 alkylene-** L1 , * L1 —C 1-8 alkyleneNR L1a C(O)—** L1 , * L1 —C 1-8 alkyleneC(O)NR L1a —** L , —C 1-8 alkylene-, —C 2-8 alkenylene- or —C 2-8 alkynylene- is optionally substituted with at least one R L1c ;

u1 and v1 are each independently selected from 1, 2, 3, 4, 5, 6, 7 or 8;

wherein * L1 refers to the position attached to the

moiety, and ** L1 refers to the position attached to the

moiety;

L 2 is selected from a single bond, —O—, —SO 2 —, —CO—, —NR L2a —, —C 3 -C 8 cycloalkylene-, * L2 O—C 1-8 alkylene-** L2 , * L —C 1-8 alkylene-O—** L2 , * L SO 2 —C 1-8 alkylene-** L2 , * L —C 1-8 alkylene-SO 2 —** L2 , * L CO—C 1-8 alkylene-** L2 , * L2 —C 1-8 alkylene-CO—** L2 , * L2 —NR L2a —C 1-8 alkylene-** L2 , * L2 —C 1-8 alkylene-NR L2a —** L2 , * L2 —NR L2a C(O)—** L2 , * L C(O)NR L2a —** L2 , * L2 —NR L2a C(O)C 1-8 alkylene-** L2 , * L —C(O)NR L2a C 1-8 alkylene-** L2 , * L2 —C 1-8 alkyleneNR 2a C(O)—** L2 , * L —C 1-8 alkyleneC(O)NR L2a —** L2 , —C 1-8 alkylene-, —C 2-8 alkenylene-, —C 2-8 alkynylene- or —[O(CR L2a R L2b ) u2 ] v2 —;

each of said —C 3 -C 8 cycloalkylene-, * L2 —O—C 1-8 alkylene-** L2 , * L2 —C 1-8 alkylene-O—** L2 , * L2 —SO 2 —C 1-8 alkylene-** L2 , * L2 —C 1-8 alkylene-SO 2 —** L2 , * L2 —CO—C 1-8 alkylene-** L2 , * L2 —C 1-8 alkylene-CO—** L2 , * L2 —NR L2a —C 1-8 alkylene-** L2 , * L2 —C 1-8 alkylene-NR L2a —** L2 , * L2 —NR L2a C(O)C 1-8 alkylene-** L2 , * L2 —C(O)NR L2a C 1-8 alkylene-** L2 , * L2 —C 1-8 alkyleneNR L2a C(O)—** L2 , * L2 —C 1-8 alkyleneC(O)NR L2a —** L2 , —C 1-8 alkylene-, —C 2-8 alkenylene- or —C 2-8 alkynylene- is optionally substituted with at least one substituent R L2c ,

u2 and v2 are each independently selected from 1, 2, 3, 4, 5, 6, 7 or 8;

wherein * L2 refers to the position attached to the

moiety, and ** L2 refers to the position attached to the

moiety;

L 3 is selected from a single bond, —O—, —SO 2 —, —CO—, —NR L3a —, —C 3 -C 8 cycloalkylene-, * L3 —O—C 1-8 alkylene-** L3 , * L3 —C 1-8 alkylene-O—** L3 , * L3 —SO 2 —C 1-8 alkylene-** L3 , * L3 —C 1-8 alkylene-SO 2 —** L3 , * L3 —CO—C 1-8 alkylene-** L3 , * L3 —C 1-8 alkylene-CO—** L3 , * L3 —NR L3a —C 1-8 alkylene-** L3 , * L3 —C 1-8 alkylene-NR L3a —** L3 , * L3 —NR L3a C(O)—** L3 , * L3 —C(O)NR L3a —** L3 , * L3 —NR L3a C(O)C 1-8 alkylene-** L3 , * L3 —C(O)NR L3a C 1-8 alkylene-** L3 , * L3 —C 1-8 alkyleneNR L3a C(O)—** L3 , * L3 —C 1-8 alkyleneC(O)NR L3a —** L3 , —C 1-8 alkylene-, —C 2-8 alkenylene-, —C 2-8 alkynylene- or —[O(CR L3a R L3b ) u3 ] v3 —; each of said —C 3 -C 8 cycloalkylene-, * L3 —O—C 1-8 alkylene-** L3 , * L3 —C 1-8 alkylene-O—** L3 , * L3 —SO 2 —C 1-8 alkylene-** L3 , * L3 —C 1-8 alkylene-SO 2 —** L3 , * L3 —CO—C 1-8 alkylene-** L3 , * L3 —C 1-8 alkylene-CO—** L3 , * L3 —NR L3a —C 1-8 alkylene-** L3 , * L3 —C 1-8 alkylene-NR L3a —** L3 , * L3 —NR L3a C(O)C 1-8 alkylene-** L3 , * L3 —C(O)NR L3a C 1-8 alkylene-** L3 , * L3 —C 1-8 alkyleneNR L3a C(O)—** L3 , * L3 —C 1-8 alkyleneC(O)NR L3a —** L3 , —C 1-8 alkylene-, —C 2-8 alkenylene-, or —C 2-8 alkynylene- is optionally substituted with at least one substituent R L3c ;

u3 and v3 are each independently selected from 1, 2, 3, 4, 5, 6, 7 or 8;

wherein * L3 refers to the position attached to the

moiety, and ** L3 refers to the position attached to the

moiety;

R L1a , R L1b , R L2a , R L2b , R L3a and R L3b are each independently selected from hydrogen, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein each of said —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl or membered-heteroaryl is optionally substituted with at least one substituent R L3d ; R L3d is halogen, hydroxy, —C 1-8 alkyl, -haloC 1-8 alkyl, —C 1-8 alkoxy, —C 2-8 alkenyl, —C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl.

33 . The compound according to claim 1 , wherein the

moiety is

wherein * refers to the position attached to the

moiety, and ** refers to the position attached to the

moiety;

X 1 , X 2 , X 3 and X 4 are each independently selected from CH or N;

r and s are each independently 0 or 1;

L 1 is a single bond, —O—, —SO 2 —, —C(O)—, —NR L1a —, —C 3 -C 8 cycloalkylene-, * L1 —O—C 1-8 alkylene-** L1 , * L1 —C 1-8 alkylene-O—** L1 , * L1 —SO 2 —C 1-8 alkylene-** L1 , * L1 —C 1-8 alkylene-SO 2 —** L1 , * L1 —C(O)—C 1-8 alkylene-** L1 , * L1 —C 1-8 alkylene-C(O)—** L1 , * L1 —NR L1a —C 1-8 alkylene-** L1 , * L1 —C 1-8 alkylene-NR L1a —** L u * L1 —NR L1a C(O)—** L1 , * L1 —C(O)NR L1a —** L1 , * L1 —NR L1a C(O)C 1-8 alkylene-** L , * L —C(O)NR L1a C 1-8 alkylene-** L , * L i-C 1-8 alkyleneNR L1a C(O)—** L , * L —C 1-8 alkyleneC(O)NR L1a —** L , —C 1-8 alkylene-, —C 2-8 alkenylene-, —C 2-8 alkynylene-, or —[O(CR L1a R L1b ) u1 ] v1 —;

each of said —C 3 -C 8 cycloalkylene-, * L —O—C 1-8 alkylene-** L1 , * L1 —C 1-8 alkylene-O—** L1 , * L1 —SO 2 —C 1-8 alkylene-** L1 , * L1 —C 1-8 alkylene-SO 2 —** L1 , * L1 —C(O)—C 1-8 alkylene-** L1 , * L1 —C 1-8 alkylene-C(O)—** L1 , * L1 —NR L1a C 1-8 alkylene-** L1 , * L1 —C 18 alkylene-NR L1a —** L1 , * L1 —NR L1a C(O)C 1-8 alkylene-** L1 , * L1 —C(O)NR L1a C 1-8 alkylene-** L1 , * L1 —C 1-8 alkyleneNR L1a C(O)—** L1 , * L1 —C 1-8 alkyleneC(O)NR L1a —** L1 , —C 1-8 alkylene-, —C 2-8 alkenylene- or —C 2-8 alkynylene- is optionally substituted with at least one R L1c ;

u1 and v1 are each independently selected from 1, 2, 3, 4, 5, 6, 7 or 8;

wherein * L1 refers to the position attached to the

moiety, and ** L1 refers to the position attached to the

moiety;

L 2 is selected from a single bond, —O—, —SO 2 —, —CO—, —NR L2a —, —C 3 -C 8 cycloalkylene-, * L2 O—C 1-8 alkylene-** L2 , * L2 —C 1-8 alkylene-O—** L2 , * L2 —SO 2 —C 1-8 alkylene-** L2 , * L2 —C 1-8 alkylene-SO 2 —** L2 , * L2 —CO—C 1 alkylene-** L2 , * L2 —C 1-8 alkylene-CO—** L2 , * L2 —NR L2a —C 1-8 alkylene-** L2 , * L2 —C 1-8 alkylene-NR L2a —** L2 , * L2 —NR 2a C(O)** L2 , * L2 —C(O)NR 2a —** L2 , * L2 —R L1a C(O)C 1-8 alkylene-** L2 , * L2 —C(O)NR L2a C 1 alkylene-** L2 , * L2 —C 1-8 alkyleneNR L2a C(O)—** L2 , * L2 —C 1-8 alkyleneC(O)NR L2a —** L , —C 1-8 alkylene-, —C 2-8 alkenylene-, —C 2-8 alkynylene- or —[O(CR L2a R L2b ) u2 ] v2 —;

each of said —C 3 -C 8 cycloalkylene-, * L2 —O—C 1-8 alkylene-** L2 , * L2 —C 1-8 alkylene-O—** L2 , * L2 SO 2 —C 1-8 alkylene-** L2 , * L2 —C 1-8 alkylene-SO 2 —** L2 , * L2 —CO—C 1-8 alkylene-** L2 , * L2 —C 1-8 alkylene-CO—** L2 , * L2 —NR L2a C 1-8 alkylene-** L2 , * L2 —C 1-8 alkylene-NR L2a —** L2 , * L NR 2a C(O)C 1-8 alkylene-** L2 , * L2 —C(O)NR L2a C 2-8 alkylene-** L2 , * L2 —C 1-8 alkyleneNR 2a C(O)—** L2 * L —C 1-8 alkyleneC(O)NR L2a —** L2 , —C 1-8 alkylene-, —C 2-8 alkenylene- or —C 2-8 alkynylene- is optionally substituted with at least one substituent R L2c ;

u2 and v2 are each independently selected from 1, 2, 3, 4, 5, 6, 7 or 8;

wherein * L2 refers to the position attached to the

moiety, and ** L2 refers to the position attached to the

moiety;

L 3 is selected from a single bond, —O—, —SO 2 —, —CO—, —NR L3a —, —C 3 -C 8 cycloalkylene-, * L3 —O—C 1-8 alkylene-** L3 , * L3 —C 1-8 alkylene-O—** L3 , * L3 —SO 2 —C 1-8 alkylene-** L3 , * L3 —C 1-8 alkylene-SO 2 —** L3 , * L3 —CO—C 1-8 alkylene-* L3 , * L3 —C 1-8 alkylene-CO—** L3 , * L3 —NR L3a —C 1-8 alkylene-** L3 , * L3 —C 1-8 alkylene-NR L3a —** L3 , * L3 —NR L3a C(O)—** L3 , * L3 —C(O)NR L3a —** L3 , * L3 —NR L3a C(O)C 1-8 alkylene-** L3 , * L3 —C(O)NR L3a C 1-8 alkylene-** L3 , * L3 —C 1-8 alkyleneNR L3a C(O)—** L3 , * L3 —C 1-8 alkyleneC(O)NR L3a —** L3 , —C 1-8 alkylene-, —C 2-8 alkenylene-, —C 2-8 alkynylene- or —[O(CR L3a R L3b ) u3 ] v3 —; each of said —C 3 -C 8 cycloalkylene-, * L3 —O—C 1-8 alkylene-** L3 , * L3 —C 1-8 alkylene-O—** L3 , * L3 —SO 2 —C 1-8 alkylene-** L3 , * L3 —C 1-8 alkylene-SO 2 —** L3 , * L3 —CO—C 1-8 alkylene-** L3 , * L3 —C 1-8 alkylene-CO—** L3 , * L3 —NR L3a —C 1-8 alkylene-** L3 , * L3 —C 1-8 alkylene-NR L3a —** L3 , * L3 —NR L3a C(O)C 1-8 alkylene-** L3 , * L3 —C(O)NR L3a C 1-8 alkylene-** L3 , * L3 —C 1-8 alkyleneNR L3a C(O)—** L3 , * L3 —C 1-8 alkyleneC(O)NR L3a —** L3 , —C 1-8 alkylene-, —C 2-8 alkenylene-, or —C 2-8 alkynylene is optionally substituted with at least one substituent R L3c ;

u3 and v3 are each independently selected from 1, 2, 3, 4, 5, 6, 7 or 8;

wherein * L3 refers to the position attached to the

moiety, and ** L3 refers to the position attached to the

moiety;

R L1a , R L1b , R L2a , R L2b , R L3a and R L3b are each independently selected from hydrogen, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein each of said —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl or membered heteroaryl is optionally substituted with at least one substituent R L3d ; R L3d is halogen, hydroxy, —C 1-8 alkyl, -haloC 1-8 alkyl, —C 1-8 alkoxy, —C 2-8 alkenyl, —C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl.

34 . The compound according to claim 32 , wherein

(a) L 1 is a single bond, —O—, —SO 2 —, —C(O)—, —NH—, —N(CH 3 )—, —N(C 2 H 5 )—, —N(C 3 H 7 )—, * L O—CH 2 —** L1 , * L1 —O—C 2 H 4 —** L1 , * L1 —O—C 3 H 6 —** L1 , * L1 —O—C 4 H 8 —** L1 , * L1 —CH 2 —O—** L1 , * L1 —C 2 H 4 —O—** L1 , * L1 —C 3 H 6 —O—** L1 , * L1 —C 4 H 8 —O—** L1 , * L1 —SO 2 —CH 2 ** L1 , * L1 —SO 2 —C 2 H 4 —** L1 , * L1 —SO 2 —C 3 H 6 —** L1 , * L1 —SO 2 —C 4 H 8 —** L1 , * L1 —CH 2 —SO 2 —** L , * L C 2 H 4 —SO 2 ** L , * L1 —C 3 H 6 —SO 2 —** L1 , * L1 —C 4 H 8 —SO 2 —** L1 , * L1 —C(O)—CH 2 —** L1 , * L1 —C(O)—C 2 H 4 —** L1 , * L C(O)—C 3 H 8 —** L1 , * L1 —C(O)—C 4 H 8 —** L1 , * L1 —CH 2 —C(O)—** L1 , * L —C 2 H 4 —C(O)—** L1 , * L —C 3 H 6 —C(O)—** L1 , * L —C 4 H 8 —C(O)—** L1 , * L —NH—CH 2 —** L1 , * L1 —NH—C 2 H 4 —** L , * L1 —NH—C 3 H 6 —** L1 , * L1 —NH—C 4 H 8 —** L1 , * L1 —CH 2 —NH—** L , * L —C 2 H 4 —NH—** L1 , * L1 —C 3 H 6 —NH—** L1 , * L1 —C 4 H 8 —NH—** L1 , * L1 —NHC(O)—** L , * L —C(O)NH—** L , * L L-N(CH 3 )C(O)—** L1 , * L1 —C(O)N(CH 3 )—** L1 , * L1 —N(C 2 H 5 )C(O)—** L1 , * L1 —C(O)N(C 2 H 5 )—** L1 , * L1 —N(C 3 H 7 )C(O)—** L1 , * L1 —C(O)N(C 3 H 7 )—** L1 , * L1 —NHC(O)CH 2 —** L1 , * L1 —NHC(O)C 2 H 4 —** L1 , * L1 —NHC(O)C 3 H 6 —** L1 , * L1 —NHC(O)C 4 H 8 —** L1 , * L1 —C(O)NHCH 2 —** L , * L —C(O)NHC 2 H 4 —** L1 , * L1 —C(O)NHC 3 H 6 —** L1 , * L1 —C(O)NHC 4 H 8 —** L1 , * L1 —CH 2 NHC(O)—** L , * L —C 2 H 4 NHC(O)—** L , * L —C 3 H 6 NHC(O)—** L , * L —C 4 H 8 NHC(O)—** L , * L —CH 2 C(O)NH—** L , * L1 —C 2 H 4 C(O)NH—** L , * L L-C 3 H 6 C(O)NH—** L , * L —C 4 H 8 C(O)NH—** L , —CH 2 —, —C 2 H 4 —, —C 3 H 6 —, —C 4 H 8 —, —O(CH 2 ) 2 —, —[O(CH 2 ) 2 ] 2 —, —[O(CH 2 ) 2 ] 3 —, —[O(CH 2 ) 2 ] 4 — or —[O(CH 2 ) 2 ] 5 —;

and/or

(b) L 2 is a single bond, —O—, —SO 2 —, —C(O)—, —NH—, —N(CH 3 )—, —N(C 2 H 5 )—, —N(C 3 H 7 )—, * L2 —O—CH 2 —** L2 , * L2 —O—C 2 H 4 —** L2 , * L2 —O—C 3 H 6 —** L2 , * L2 —O—C 4 H 8 —** L2 , * L2 —CH 2 —O—** L2 , * L2 —C 2 H 4 —O—** L2 , * L2 —C 3 H 6 —O—** L2 , * L2 —C 4 H 8 —O—** L2 , * L2 —SO 2 —CH 2 —** L2 , * L2 —SO 2 —C 2 H 4 —** L2 , * L2 —SO 2 —C 3 H 6 —** L2 , * L2 —SO 2 —C 4 H 8 —** L2 , * L2 —CH 2 —SO 2 —** L2 , * L2 —C 2 H 4 —SO 2 —** L2 , * L2 —C 3 H 6 —SO 2 —** L2 , * L2 —C 4 H 8 —SO 2 —**L 2 , * L2 , * L2 —C(O)—CH 2 —** L2 , * L2 —C(O)—C 2 H 4 —** L2 , * L2 —C(O)—C 3 H 6 —** L2 , * L2 —C(O)—C 4 H 8 —** L2 , * L2 —CH 2 —C(O)—** L2 , * L2 —C 2 H 4 —C(O)—** L2 , * L2 —C 3 H 6 —C(O)—** L2 , * L2 —C 4 H 8 —C(O)—** L2 , * L2 —NH—CH 2 —** L2 , * L2 —NH—C 2 H 4 —** L2 , * L2 —NH—C 3 H 6 —** L2 , * L2 —NH—C 4 H 8 —** L2 , * L2 —CH 2 —NH—** L2 , * L2 —C 2 H 4 —NH—** L2 , * L2 —C 3 H 6 —NH—** L2 , * L2 —C 4 H 8 —NH—** L2 , * L2 —NHC(O)—** L2 , * L2 —C(O)NH—** L2 , * L2 —N(CH 3 )C(O)—** L2 , * L2 —C(O)N(CH 3 )—** L2 , * L2 —N(C 2 H 5 )C(O)—** L2 , * L2 —C(O)N(C 2 H 5 )—** L2 , * L2 —N(C 3 H 7 )C(O)—** L2 , * L2 —C(O)N(C 3 H 7 )—** L2 , * L2 —NHC(O)CH 2 —** L2 , * L2 —NHC(O)C 2 H 4 —** L2 , * L2 —NHC(O)C 3 H 6 —** L2 , * L2 —NHC(O)C 4 H 8 —** L2 , * L2 —C(O)NHCH 2 —** L2 , * L2 —C(O)NHC 2 H 4 —** L2 , * L2 —C(O)NHC 3 H 6 —** L2 , * L2 —C(O)NHC 4 H 8 —** L2 , * L2 —CH 2 NHC(O)—** L2 , * L2 —C 2 H 4 NHC(O)—** L2 , * L2 —C 3 H 6 NHC(O)—** L2 , * L2 —C 4 H 8 NHC(O)—** L2 , * L2 —CH 2 C(O)NH—** L2 , * L2 —C 2 H 4 C(O)NH—** L2 , * L2 —C 3 H 6 C(O)NH—** L2 , * L2 —C 4 H 8 C(O)NH—** L2 , —CH 2 —, —C 2 H 4 —, —C 3 H 6 —, —C 4 H 8 —, —O(CH 2 ) 2 —, —[O(CH 2 ) 2 ] 2 —, —[O(CH 2 ) 2 ] 3 —, —[O(CH 2 ) 2 ] 4 — or —[O(CH 2 ) 2 ] 5 —,

and/or

(c) L 3 is a single bond, —O—, —SO 2 —, —C(O)—, —NH—, —N(CH 3 )—, —N(C 2 H 5 )—, —N(C 3 H 7 )—, * L3 —O—CH 2 —** L3 , * L3 —O—C 2 H 4 —** L3 , * L3 —O—C 3 H 6 —** L3 , * L3 —O—C 4 H 8 —** L3 , * L3 —CH 2 —O—** L3 , * L3 —C 2 H 4 —O—** L3 , * L3 —C 3 H 6 —O—** L3 , * L3 —C 4 H 8 —O—** L3 , * L3 —SO 2 —CH 2 —** L3 , * L3 —SO 2 —C 2 H 4 —** L3 , * L3 —SO 2 —C 3 H 6 —** L3 , * L3 —SO 2 —C 4 H 8 —** L3 , * L3 —CH 2 —SO 2 —** L3 , * L3 —C 2 H 4 —SO 2 —** L3 , * L3 —C 3 H 6 —SO 2 —** L3 , * L3 —C 4 H 8 —SO 2 —** L3 , * L3 —C(O)—CH 2 —** L3 , * L3 —C(O)—C 2 H 4 —** L3 , * L3 —C(O)—C 3 H 6 —** L3 , * L3 —C(O)—C 4 H 8 —** L3 , * L3 —CH 2 —C(O)—** L3 , * L3 —C 2 H 4 —C(O)—** L3 , * L3 —C 3 H 6 —C(O)—** L3 , * L3 —C 4 H 8 —C(O)—** L3 , * L3 —NH—CH 2 —** L3 , * L3 —NH—C 2 H 4 —** L3 , * L3 —NH—C 3 H 6 —** L3 , * L3 —NH—C 4 H 8 —** L3 , * L3 —CH 2 —NH—** L3 , * L3 —C 2 H 4 —NH—** L3 , * L3 —C 3 H 6 —NH—** L3 , * L3 —C 4 H 8 —NH—** L3 , * L3 —NHC(O)—** L3 , * L3 —C(O)NH—** L3 , * L3 —N(CH 3 )C(O)—** L3 , * L3 —C(O)N(CH 3 )—** L3 , * L3 —N(C 2 H 5 )C(O)—** L3 , * L3 —C(O)N(C 2 H 5 )—** L3 , * L3 —N(C 3 H 7 )C(O)—** L3 , * L3 —C(O)N(C 3 H 7 )—** L3 , * L3 —NHC(O)CH 2 —** L3 , * L3 —NHC(O)C 2 H 4 —** L3 , * L3 —NHC(O)C 3 H 6 —** L3 , * L3 —NHC(O)C 4 H 8 —** L3 , * L3 —C(O)NHCH 2 —** L3 , * L3 —C(O)NHC 2 H 4 —** L3 , * L3 —C(O)NHC 3 H 6 —** L3 , * L3 —C(O)NHC 4 H 8 —** L3 , * L3 —CH 2 NHC(O)—** L3 , * L3 —C 2 H 4 NHC(O)—** L3 , * L3 —C 3 H 6 NHC(O)—** L3 , * L3 —C 4 H 8 NHC(O)—** L3 , * L3 —CH 2 C(O)NH—** L3 , * L3 —C 2 H 4 C(O)NH—** L3 , * L3 —C 3 H 6 C(O)NH—** L3 , * L3 —C 4 H 8 C(O)NH—** L3 , —CH 2 —, —C 2 H 4 —, —C 3 H 6 —, —C 4 H 8 —, —O(CH 2 ) 2 —, —[O(CH 2 ) 2 ] 2 —, —[O(CH 2 ) 2 ] 3 —, —[O(CH 2 ) 2 ] 4 — or —[O(CH 2 ) 2 ] 5 —.

35 . (canceled)

36 . (canceled)

37 . The compound according to claim 32 , wherein the

moiety is independently selected from

wherein * X1 refers to the position attached to the

moiety, and ** X2 refers to the position attached to the

moiety.

38 . The compound according to claim 32 , wherein the

moiety is independently selected from

wherein * X3 refers to the position attached to the

moiety, and ** L4 refers to the position attached to the

moiety.

39 . The compound according to claim 33 , wherein the

moiety is

wherein * refers to the position attached to the

moiety, and ** refers to the position attached to the

moiety.

40 . A compound selected from

or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof.

41 . A prodrug of the compound according to claim 1 , wherein the N atom of the compound is substituted with R pro , R pro is —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each of said —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with R proa ; R proa is independently selected from hydrogen, halogen, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, —CN, —NO 2 , —OR prob , —OCOR prob , —COR prob , —CO 2 R prob , —CONR prob R proc , —NR prob R proc , —NR prob COR proc , —NR prob CONR proc R prod , or —NR prob CO 2 R proc wherein R prob , R proc , R prod are each independently selected from —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkyl-C 1-8 alkyl-, heterocyclyl-C 1-8 alkyl-, aryl-C 1-8 alkyl-, or heteroaryl-C 1-8 alkyl-.

42 . The prodrug of claim 41 , wherein R pro is

43 . A prodrug selected from

or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof.

44 . A pharmaceutical composition comprising the compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.

45 . A method of inhibiting BTK activity, which comprises administering to a subject in need thereof an effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

46 . A method of treating a disease or disorder in a patient in need thereof comprising administering to the patient a therapeutically effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof as an BTK kinase inhibitor, wherein the disease or disorder is associated with inhibition of BTK, preferably, the disease or disorder is cancer.